Overview

Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease

Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of E1224, a pro-drug of ravuconazole, in individuals with chronic indeterminate Chagas disease recruited in research centres in Tarija and Cochabamba, Bolivia.
Phase:
Phase 2
Details
Lead Sponsor:
Drugs for Neglected Diseases
Collaborator:
Eisai Co., Ltd.
Treatments:
Benzonidazole